Literature DB >> 28967900

Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.

X Zheng1, J Chi1, J Zhi1, H Zhang2, D Yue3, J Zhao1, D Li1, Y Li1, M Gao1, J Guo4.   

Abstract

Deletion or loss-of-function mutation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant caution of NSCLC initiation and progression. However, the upstream signaling pathways governing LKB1 activation are largely unknown. Here, we report that LKB1 undergoes Aurora kinase A (AURKA)-mediated phosphorylation, which largely compromises the LKB1/AMPK signaling axis, in turn leading to the elevation of NSCLC cell proliferation, invasion and migration. Mechanically, AURKA-mediated phosphorylation of LKB1 impairs LKB1 interaction with and phosphorylation of its downstream target AMPKα, which has critical roles in governing cancer cell energy metabolic homeostasis and tumorigenesis. Clinically, AURKA displays high levels in NSCLC patients, and correlates with poor outcome of patients with lung adenocarcinoma. Pathologically, the amplification or activation of AURKA-induced impairment of the LKB1/AMPK signaling pathway contributes to NSCLC initiation and progression, highlighting AURKA as a potential therapeutic target for combatting hyperactive AURKA-driven NSCLCs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28967900     DOI: 10.1038/onc.2017.354

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

1.  Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Daruka Mahadevan; Amy Stejskal; Laurence S Cooke; Ann Manziello; Carla Morales; Daniel O Persky; Richard I Fisher; Thomas P Miller; Wenqing Qi
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

Review 2.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

Review 3.  Discovery and development of aurora kinase inhibitors as anticancer agents.

Authors:  John R Pollard; Michael Mortimore
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

4.  Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Authors:  Ami V Patel; David Eaves; Walter J Jessen; Tilat A Rizvi; Jeffrey A Ecsedy; Mark G Qian; Bruce J Aronow; John P Perentesis; Eduard Serra; Timothy P Cripe; Shyra J Miller; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2012-07-18       Impact factor: 12.531

5.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Authors:  Mahvash Zakikhani; Ryan Dowling; I George Fantus; Nahum Sonenberg; Michael Pollak
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

6.  Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer.

Authors:  J Carretero; P P Medina; R Blanco; L Smit; M Tang; G Roncador; L Maestre; E Conde; F Lopez-Rios; H C Clevers; M Sanchez-Cespedes
Journal:  Oncogene       Date:  2006-09-04       Impact factor: 9.867

7.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner.

Authors:  Jianping Guo; Abhishek A Chakraborty; Pengda Liu; Wenjian Gan; Xingnan Zheng; Hiroyuki Inuzuka; Bin Wang; Jinfang Zhang; Linli Zhang; Min Yuan; Jesse Novak; Jin Q Cheng; Alex Toker; Sabina Signoretti; Qing Zhang; John M Asara; William G Kaelin; Wenyi Wei
Journal:  Science       Date:  2016-08-26       Impact factor: 47.728

Review 8.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

9.  Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.

Authors:  Elton Zeqiraj; Beatrice Maria Filippi; Maria Deak; Dario R Alessi; Daan M F van Aalten
Journal:  Science       Date:  2009-11-05       Impact factor: 47.728

10.  Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.

Authors:  X Q Zheng; J P Guo; H Yang; M Kanai; L L He; Y Y Li; J M Koomen; S Minton; M Gao; X B Ren; D Coppola; J Q Cheng
Journal:  Oncogene       Date:  2013-10-28       Impact factor: 9.867

View more
  16 in total

1.  Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.

Authors:  Claudia Ctortecka; Vinayak Palve; Brent M Kuenzi; Bin Fang; Natalia J Sumi; Victoria Izumi; Silvia Novakova; Fumi Kinose; Lily L Remsing Rix; Eric B Haura; John Matthew Koomen; Uwe Rix
Journal:  Mol Cell Proteomics       Date:  2018-09-14       Impact factor: 5.911

Review 2.  Controlling the master-upstream regulation of the tumor suppressor LKB1.

Authors:  Lars Kullmann; Michael P Krahn
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

3.  Integrative Analysis for Identification of Therapeutic Targets and Prognostic Signatures in Non-Small Cell Lung Cancer.

Authors:  Özgür Cem Erkin; Betül Cömertpay; Esra Göv
Journal:  Bioinform Biol Insights       Date:  2022-04-06

4.  Identification of novel biomarkers and small molecule drugs in human colorectal cancer by microarray and bioinformatics analysis.

Authors:  Juan Chen; Ziheng Wang; Xianjuan Shen; Xiaopeng Cui; Yuehua Guo
Journal:  Mol Genet Genomic Med       Date:  2019-05-13       Impact factor: 2.183

5.  Identification of driver genes associated with chemotherapy resistance of Ewing's sarcoma.

Authors:  Hongyi Liao; Xianbiao Xie; Yuanyuan Xu; Gang Huang
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.147

6.  FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.

Authors:  Xiao-Na Zhu; Ping He; Liang Zhang; Shuo Yang; Hui-Lin Zhang; Di Zhu; Meng-Di Liu; Yun Yu
Journal:  Cell Death Dis       Date:  2019-06-19       Impact factor: 8.469

7.  Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions.

Authors:  Katherine N Lynch; Joyce F Liu; Nikolas Kesten; Kin-Hoe Chow; Aniket Shetty; Ruiyang He; Mosammat Faria Afreen; Liping Yuan; Ursula A Matulonis; Whitfield B Growdon; Michael G Muto; Neil S Horowitz; Colleen M Feltmate; Michael J Worley; Ross S Berkowitz; Christopher P Crum; Bo R Rueda; Sarah J Hill
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

8.  Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling.

Authors:  Liankang Sun; Junyu Cao; Ke Chen; Liang Cheng; Cancan Zhou; Bin Yan; Weikun Qian; Jie Li; Wanxing Duan; Jiguang Ma; Dan Qi; Erxi Wu; Zheng Wang; Qingguang Liu; Qingyong Ma; Qinhong Xu
Journal:  Int J Oncol       Date:  2018-10-24       Impact factor: 5.650

9.  C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation.

Authors:  Chenhui Zhao; Yongting Li; Wen Qiu; Fengxia He; Weiming Zhang; Dan Zhao; Zhiwei Zhang; Erbao Zhang; Pei Ma; Yiqian Liu; Ling Ma; Fengming Yang; Yingwei Wang; Yongqian Shu
Journal:  Oncogene       Date:  2018-05-18       Impact factor: 9.867

Review 10.  Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.

Authors:  A Pavan; I Attili; G Pasello; V Guarneri; P F Conte; L Bonanno
Journal:  J Immunother Cancer       Date:  2019-08-05       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.